Copernicus Therapeutics, Inc. To Receive Increased Support From Cystic Fibrosis Foundation Therapeutics, Inc. To Further Development Of Its Non-Viral Gene Therapy For Cystic Fibrosis

CLEVELAND--(BUSINESS WIRE)--Copernicus Therapeutics, Inc., announced today it will receive up to $5.2 million from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) to support continued development of a potential gene therapy for cystic fibrosis. This continued funding is a result of satisfactory progress shown in 2006 and represents a significant increase in funding over that received in 2006.